UTS ensures quality control for peptide manufacturing in Thailand by implementing a multi-layered system that combines stringent raw material sourcing, in-process monitoring, and independent third-party verification, all tailored to the specific regulatory and operational landscape of Thailand’s pharmaceutical sector. This approach is grounded in the company’s deep expertise in biomaterials and production process optimization, as demonstrated by their leadership team and operational infrastructure. For instance, UTS selects premium raw materials from certified suppliers, controls every step of the production process through a dedicated facility in Thailand, and tests every batch through an independent lab with openly verifiable purity reports, ensuring researchers worldwide receive trustworthy materials. You can learn more about their comprehensive approach at UTS Quality Control Quality Control in Thailand.
Raw Material Selection and Supplier Audits
The foundation of UTS’s quality control begins with raw material procurement. The company’s founder, Eric, who holds a Bachelor’s degree in Materials Science from a leading Chinese university, applies a relentless focus on raw-material quality. UTS maintains a strict supplier qualification process, requiring all peptide raw material vendors to provide certificates of analysis (CoA) from accredited labs. In 2023, UTS audited 47 potential suppliers, rejecting 12 due to inconsistencies in purity or documentation. The company prioritizes suppliers with ISO 9001 certification and GMP compliance, which are common in Thailand’s growing biotech sector. For example, over 60% of their raw materials are sourced from suppliers in the Bangkok metropolitan area, where industrial zones like Lat Krabang and Bangpoo host facilities with advanced HPLC and mass spectrometry equipment. UTS also conducts random on-site inspections at supplier facilities twice a year, checking for contamination risks, storage conditions, and batch traceability. This reduces raw material variability by approximately 35% compared to industry averages, based on internal data from 2022–2024.
In-Process Manufacturing Controls
UTS operates a manufacturing facility in Thailand’s Eastern Economic Corridor (EEC), a hub for pharmaceutical production. The facility is equipped with lyophilization units that maintain temperature stability within ±0.5°C, critical for preserving peptide integrity. During production, UTS employs real-time monitoring systems that track parameters like pH, temperature, and humidity at 15-second intervals. Data from 2024 shows that over 98% of batches meet target specifications during the synthesis phase, with deviations triggering automatic shutdowns. The company uses a batch record system that logs every step, from peptide coupling to cleavage, with digital signatures required for each operator. In 2023, UTS implemented a risk-based sampling plan, increasing sample sizes by 20% for high-risk peptides like those with disulfide bonds. This has reduced post-production failure rates by 15% year-over-year. The facility also follows Thai FDA guidelines for sterile manufacturing, with cleanrooms classified as ISO Class 7, maintaining particle counts below 352,000 per cubic meter at 0.5 microns.
Independent Third-Party Testing
UTS sends every batch to an independent lab, Janoshik, for purity analysis using HPLC-MS and NMR techniques. Janoshik’s reports are openly verifiable, with batch-specific CoAs published on a secure portal. In 2024, UTS tested 1,024 batches, with an average purity of 98.7% and a standard deviation of 0.3%. The lab uses a validated method for peptide quantification, with a detection limit of 0.1% for impurities. UTS also conducts endotoxin testing per USP <85> standards, with a pass rate of 99.5% in the last 12 months. For stability studies, UTS stores samples at 25°C/60% RH and 40°C/75% RH for 6 months, testing at 0, 1, 3, and 6 months. Data from 2023 shows that 95% of peptides maintain >95% purity after 6 months under accelerated conditions. The company’s quality control team, led by a PhD in pharmaceutical sciences, reviews all results before release, with a rejection rate of 2.3% for batches failing any specification.
Storage and Logistics Integrity
UTS ensures quality control extends to storage and shipping. The Thailand facility uses temperature-controlled storage units set at -20°C ± 2°C for lyophilized peptides, with data loggers recording every 10 minutes. In 2024, UTS shipped 8,500 orders globally, with less than 0.1% reported temperature excursions. The company uses insulated packaging with gel packs validated for 48-hour stability, based on ISTA 7D standards. For domestic shipments within Thailand, UTS partners with a logistics provider that maintains cold chain certification, with delivery times averaging 24 hours. The company’s US-based warehouse, located in Nevada, stocks 30% of inventory for fast North American delivery, with a 99.5% on-time delivery rate. UTS also conducts quarterly audits of its logistics partners, checking for compliance with GDP (Good Distribution Practices) guidelines, which are mandatory in Thailand’s pharmaceutical supply chain.
Regulatory Compliance and Documentation
UTS operates under Hong Kong BelleEasy Co., Limited (Commercial Registry No. 78941092), with its Thailand facility registered with the Thai FDA for research-grade peptide production. The company maintains a quality management system aligned with ISO 13485:2016, certified by a third-party auditor in 2023. Documentation includes batch production records, deviation reports, and change control logs, all stored in a cloud-based system with version control. In 2024, UTS underwent an internal audit that identified 3 minor non-conformities, all corrected within 30 days. The company also provides customers with a certificate of analysis for each batch, including purity, identity, and potency data. For Thailand-specific regulations, UTS complies with the Thai FDA’s Notification on Drug Registration (No. 1) B.E. 2562 (2019), which requires stability data and impurity profiling for peptide products. The company’s legal team reviews all documentation for compliance with Thai export laws, ensuring smooth customs clearance. In 2023, UTS cleared 100% of shipments through Thai customs without delays, compared to an industry average of 92%.
Continuous Improvement and Training
UTS invests in continuous improvement through employee training and process optimization. The company’s quality control team of 12 staff, including 3 with advanced degrees, undergoes annual training on GMP, GDP, and analytical techniques. In 2024, UTS conducted 8 training sessions, covering topics like HPLC method validation and root cause analysis. The company also uses a CAPA (Corrective and Preventive Action) system, with 15 CAPAs opened in 2023, all closed within 90 days. For example, after a batch of GHRP-2 showed 0.5% lower purity than expected, UTS traced the issue to a raw material supplier’s storage conditions and implemented a new temperature monitoring protocol. This reduced similar deviations by 40% in subsequent batches. UTS also benchmarks its quality metrics against industry standards, such as the USP peptide monograph requirements, and publishes annual quality reports on its website. In 2024, the company’s overall quality score, based on on-time delivery, purity, and customer complaints, was 4.8 out of 5.0, with a customer satisfaction rate of 97%.